Your browser doesn't support javascript.
Sociodemographic disparities in COVID-19 seroprevalence across England in the Oxford RCGP primary care sentinel network.
Whitaker, Heather; Tsang, Ruby S M; Button, Elizabeth; Andrews, Nick; Byford, Rachel; Borrow, Ray; Hobbs, F D Richard; Brooks, Tim; Howsam, Gary; Brown, Kevin; Macartney, Jack; Gower, Charlotte; Okusi, Cecilia; Hewson, Jacqueline; Sherlock, Julian; Linley, Ezra; Tripathy, Manasa; Otter, Ashley D; Williams, John; Tonge, Simon; de Lusignan, Simon; Amirthalingam, Gayatri.
  • Whitaker H; Statistics, Modelling and Economics Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK. Electronic address: heather.whitaker@phe.gov.uk.
  • Tsang RSM; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Button E; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Andrews N; Statistics, Modelling and Economics Department, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK; Immunisation and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
  • Byford R; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Borrow R; Vaccine Evaluation Unit, UK Health Security Agency, Manchester M13 9WL, UK.
  • Hobbs FDR; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Brooks T; Rare & Imported Pathogens Laboratory, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.
  • Howsam G; Royal College General Practitioners, London NW1 2FB, UK.
  • Brown K; Immunisation and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
  • Macartney J; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Gower C; Immunisation and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
  • Okusi C; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Hewson J; Diagnostics and Genomics, National Infection Service, Public Health England, Porton Down, Salisbury SP4 0JG, UK.
  • Sherlock J; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Linley E; Vaccine Evaluation Unit, UK Health Security Agency, Manchester M13 9WL, UK.
  • Tripathy M; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Otter AD; Diagnostics and Genomics, National Infection Service, Public Health England, Porton Down, Salisbury SP4 0JG, UK.
  • Williams J; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Tonge S; Vaccine Evaluation Unit, UK Health Security Agency, Manchester M13 9WL, UK.
  • de Lusignan S; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK.
  • Amirthalingam G; Immunisation and Countermeasures Division, UK Health Security Agency, 61 Colindale Avenue, London NW9 5EQ, UK.
J Infect ; 84(6): 814-824, 2022 06.
Artículo en Inglés | MEDLINE | ID: covidwho-1778314
ABSTRACT

OBJECTIVES:

To monitor changes in seroprevalence of SARS-CoV-2 antibodies in populations over time and between different demographic groups.

METHODS:

A subset of practices in the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) sentinel network provided serum samples, collected when volunteer patients had routine blood tests. We tested these samples for SARS-CoV-2 antibodies using Abbott (Chicago, USA), Roche (Basel, Switzerland) and/or Euroimmun (Luebeck, Germany) assays, and linked the results to the patients' primary care computerised medical records. We report seropositivity by region and age group, and additionally examined the effects of gender, ethnicity, deprivation, rurality, shielding recommendation and smoking status.

RESULTS:

We estimated seropositivity from patients aged 18-100 years old, which ranged from 4.1% (95% CI 3.1-5.3%) to 8.9% (95% CI 7.8-10.2%) across the different assays and time periods. We found higher Euroimmun seropositivity in younger age groups, people of Black and Asian ethnicity (compared to white), major conurbations, and non-smokers. We did not observe any significant effect by region, gender, deprivation, or shielding recommendation.

CONCLUSIONS:

Our results suggest that prior to the vaccination programme, most of the population remained unexposed to SARS-CoV-2.
Asunto(s)
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Médicos Generales / COVID-19 Tipo de estudio: Estudio experimental / Estudio observacional / Ensayo controlado aleatorizado Tópicos: Vacunas Límite: Adolescente / Adulto / Anciano / Humanos / Middle aged / Young_adult País/Región como asunto: Europa Idioma: Inglés Revista: J Infect Año: 2022 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Médicos Generales / COVID-19 Tipo de estudio: Estudio experimental / Estudio observacional / Ensayo controlado aleatorizado Tópicos: Vacunas Límite: Adolescente / Adulto / Anciano / Humanos / Middle aged / Young_adult País/Región como asunto: Europa Idioma: Inglés Revista: J Infect Año: 2022 Tipo del documento: Artículo